Gilead renews partnership with Cigalah to boost Saudi healthcare

SAUDI ARABIA — Gilead Sciences, an American biopharmaceutical business, has announced the renewal and expansion of its cooperation with Cigalah Healthcare, a prominent  Saudi healthcare provider.

This collaboration, set to continue through 2026, aims to advance patient care and improve access to essential medicines in Saudi Arabia.

The new agreement encompasses a comprehensive distribution arrangement, allowing Cigalah Healthcare to secure distribution rights for Gilead’s products across its various therapeutic areas.

This strategic move is expected to enhance the availability of innovative treatments for patients throughout the kingdom.

Earlier this year, Gilead Sciences made significant strides in the region by establishing and launching its fully operational affiliate, Gilead Sciences Arabia.

This local presence is designed to enable direct access to healthcare providers and boost patient support initiatives.

By having a dedicated affiliate in Saudi Arabia, Gilead is better positioned to understand and address the unique healthcare needs of the local population.

Commenting on the renewed partnership, Vitor Papao, General Manager of Gilead Sciences in the Middle East, emphasized the importance of their collaboration with Cigalah Healthcare.

He noted that this partnership is integral to Gilead’s mission of expanding access to innovative treatments within the kingdom.

Papao highlighted that this initiative aligns closely with Saudi Arabia’s Vision 2030, a transformative agenda aimed at enhancing the healthcare sector to meet the needs of every member of society.

Papao further stated that the renewed agreement positions Gilead to leverage Cigalah’s extensive network to reach even more patients nationwide.

This collaboration is expected to play a pivotal role in transforming Saudi Arabia’s healthcare landscape, ensuring that cutting-edge treatments are accessible to those who need them most.

Yasser Yousuf Naghi, CEO of Cigalah Healthcare, expressed his enthusiasm for the continued partnership with Gilead.

He mentioned that Gilead, a global leader in innovative pharmaceutical solutions for Virology, Infectious Disease, and Oncology, brings valuable expertise to the table.

This collaboration offers Cigalah the opportunity to gain insights into highly specialized and innovative therapy areas, ultimately contributing to realizing the Health Sector Transformation Programme.

Naghi underscored that by working together, Cigalah and Gilead are well-equipped to serve their community more effectively.

 The partnership not only enhances the distribution of advanced treatments but also supports the broader goals of Vision 2030, which include improving healthcare outcomes and ensuring that the Saudi population has access to the best possible medical care.